# GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)

> **NCT04196413** · PHASE1 · RECRUITING · sponsor: **Stanford University** · enrollment: 97 (estimated)

## Conditions studied

- Glioma of Spinal Cord
- Glioma of Brainstem

## Interventions

- **DRUG:** GD2 CAR T cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04196413
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-06-04
- **Primary completion:** 2028-07-31
- **Final completion:** 2043-07-31
- **Target enrollment:** 97 (ESTIMATED)
- **Last updated:** 2026-01-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04196413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04196413, "GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04196413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*